PATRICIA GONCALVES DE ALMEIDA

(Fonte: Lattes)
Índice h a partir de 2011
1
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico

Filtros

Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 3 de 3
  • bookPart
    Atenção primária à saúde da mulher adolescente
    (2021) SORPRESO, Isabel Cristina Esposito; ALMEIDA, Patrícia Gonçalves de; TAKIUTI, Albertina Duarte; JúNIOR, José Maria Soares; BARACAT, Edmund Chada
  • article 1 Citação(ões) na Scopus
    Etonogestrel-releasing contraceptive implant in a patient using thalidomide for the treatment of erythema nodosum leprosum: a case report
    (2022) FERREIRA-FILHO, Edson Santos; BAHAMONDES, Luis; DUARTE, Daniele Coelho; GUIMARAES, Ana Lucia Monteiro; ALMEIDA, Patricia Goncalves de; SOARES-JUNIOR, Jose Maria; BARACAT, Edmund Chada; SORPRESO, Isabel Cristina Esposito
    Introduction Thalidomide is an immunomodulatory drug and first choice in the treatment of erythema nodosum leprosum. Given its teratogenic potential, it is essential that an effective contraceptive method is used, especially a long-acting reversible contraceptive (LARC) method. The subdermal etonogestrel (ENG)-releasing implant is an adequate method due to the high effectiveness and long-term use. However, interaction between thalidomide and ENG has not been well documented. Concern arises because thalidomide interacts with cytochrome P450 (CYP450) enzymes that metabolize sexual steroids. AIM: We aimed to study the effectiveness and safety of the ENG-implant in a thalidomide user. Methods Case report of a sexually active 21-year-old patient with both Hansen's disease and leprosy reaction type 2 treated with thalidomide requiring effective contraception. Follow-up was up to 36 months after implant placement. Results Contraception with ENG-implant was effective and safe, based on clinical parameters (reduction of menstrual flow and cervical mucus thickening) and laboratory parameters (gonadotropins and sexual steroids). Conclusion To the best of our knowledge, this is the first case reported which presents a patient in simultaneous use of thalidomide and ENG-implant. Although this case report preliminary supports effectiveness and safety of ENG-implant as a contraceptive option in women using thalidomide, rigorous drug-drug interaction research is needed to better characterize the interaction between thalidomide and the ENG-implant.
  • bookPart
    Anticoncepção para adolescente moradora de rua
    (2021) SORPRESO, Isabel Cristina Esposito; ALMEIDA, Patrícia Gonçalves de; TAKIUTI, Albertina Duarte; FERREIRA FILHO, Edson Santos; JúNIOR, José Maria Soares; BARACAT, Edmund Chada